5F-ADB-PINACA

5F-ADB-PINACA
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;
CAS Number	1863065-90-0;
PubChem CID	119058050;
ChemSpider	52085408;
UNII	LOL2KQM530;
CompTox Dashboard (EPA)	DTXSID301016736 ;
Chemical and physical data
Formula	C19H27FN4O2
Molar mass	362.449 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)[C@@H](C(=O)N)NC(=O)c1c2ccccc2n(n1)CCCCCF;
	InChI InChI=1S/C19H27FN4O2/c1-19(2,3)16(17(21)25)22-18(26)15-13-9-5-6-10-14(13)24(23-15)12-8-4-7-11-20/h5-6,9-10,16H,4,7-8,11-12H2,1-3H3,(H2,21,25)(H,22,26)/t16-/m1/s1; Key:SOYDDJYBRCNNIT-MRXNPFEDSA-N;

5F-ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB₁ receptor and CB₂ receptor with EC₅₀ values of 0.24 nM and 2.1 nM respectively.^[1]^[2]

Metabolism

Twelve 5F-ADB-PINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic reactions included oxidative defluorination followed by carboxylation.^[3]

Legality

5F-ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.^[4]

References

^ Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
^ "5F-ADB-PINACA". Cayman Chemical.
^ Carlier J, Diao X, Scheidweiler KB, Huestis MA (May 2017). "Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry". Clinical Chemistry. 63 (5): 1008–1021. doi:10.1373/clinchem.2016.267575. PMID 28302730.
^ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 24 July 2015.

[1] Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.

[2] "5F-ADB-PINACA". Cayman Chemical.

[3] Carlier J, Diao X, Scheidweiler KB, Huestis MA (May 2017). "Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry". Clinical Chemistry. 63 (5): 1008–1021. doi:10.1373/clinchem.2016.267575. PMID 28302730.

[4] "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 24 July 2015.

[1]

[2]

[3]

[4]

Metabolism

Legality

See also

References